Search
164 studies match these filters. Showing 76–100 of 164 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT06297291 | Global Paradise System US Post Approval Study The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 43 sites in total · contact listed | Recruiting | 1,000target | 43 / 1 | 2024 | Aug 12, 2026 | ||
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) out… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 557 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 3,110target | 557 / 35 | 2022 | Aug 11, 2026 | |
| NCT06215716 | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 356 sites in total | Recruiting | Phase 3 | 1,650target | 356 / 18 | 2023 | Aug 7, 2026 | |
| NCT06880055 | Shield Post-Approval Study Protocol The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi… ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 69 sites in total | Recruiting | 3,375target | 69 / 1 | 2025 | Aug 7, 2026 | ||
| NCT06571669 | BOOM-IBD2 Pivotal Clinical Trial Ulcerative colitis is a long-lasting condition that causes swelling and sores in the large intestine. This study tests whether a small device placed under the skin can help reduce bowel urgency in people with ulcerative colitis. The investigational device sends mild signals to a nerve near the tailb… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 19 sites in total · contact listed | Recruiting | Not applicable | 137target | 19 / 1 | 2025 | Aug 6, 2026 | |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemoth… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 846 sites in total · contact listed | Recruiting | Phase 3 | 1,295target | 846 / 3 | 2023 | Aug 5, 2026 | |
| NCT06588855 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 200 sites in total | Recruiting | Phase 3 | 350target | 200 / 30 | 2024 | Aug 5, 2026 | |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immun… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 1,151 sites in total | Recruiting | Phase 3 | 1,210target | 1,151 / 2 | 2020 | Sep 8, 2026 | |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 231 sites in total | Recruiting | Phase 3 | 540target | 231 / 24 | 2025 | Sep 3, 2026 | |
| NCT06547489 | Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 34 sites in total | Recruiting | Phase 2 | 164target | 34 / 1 | 2025 | Aug 3, 2026 | |
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 29 sites in total · contact listed | Recruiting | Phase 2 | 120target | 29 / 1 | 2026 | Jul 30, 2026 | |
| NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 25 sites in total · contact listed | Recruiting | Phase 2 | 323target | 25 / 3 | 2026 | Jul 30, 2026 | |
| NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 103 sites in total · contact listed | Recruiting | Phase 2 | 240target | 103 / 20 | 2022 | Jul 30, 2026 | |
| NCT05655182 | A Study of BLB-201 RSV Vaccine in Infants and Children This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 m… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 16 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 137target | 16 / 1 | 2023 | Jul 29, 2026 | |
| NCT03899155 | Pan Tumor Rollover Study Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 399 sites in total | Recruiting | Phase 2 | 1,500target | 399 / 38 | 2019 | Jul 29, 2026 | |
| NCT07045194 | Virtue® SAB in the Treatment of Coronary ISR Trial A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 15 sites in total · contact listed | Recruiting | Not applicable | 740target | 15 / 1 | 2025 | Jul 23, 2026 | |
| NCT06915233 | A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 7 sites in total · contact listed | Recruiting | Phase 3 | 309target | 7 / 1 | 2026 | Jul 23, 2026 | |
| NCT06932263 | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids. ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 221 sites in total | Recruiting | Phase 2 | 540target | 221 / 21 | 2025 | Jul 20, 2026 | |
| NCT05946629 | SELUTION 4 De Novo Small Vessel IDE Trial Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-mark… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 70 sites in total · contact listed | Recruiting | Not applicable | 960target | 70 / 2 | 2023 | Jul 16, 2026 | |
| NCT06937177 | Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) o… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 26 sites in total · contact listed | Recruiting | Phase 2 | 120target | 26 / 2 | 2025 | Jul 15, 2026 | |
| NCT05712200 | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy. ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 789 sites in total · contact listed | Recruiting | Phase 3 | 2,500target | 789 / 35 | 2022 | Jul 13, 2026 | |
| NCT06582810 | Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · contact listed | Recruiting | 20target | 1 / 1 | 2025 | Jul 10, 2026 | ||
| NCT04142437 | Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other place… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 76 sites in total | Recruiting | 150target | 76 / 26 | 2020 | Jul 7, 2026 | ||
| NCT05378347 | Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follo… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 68 sites in total · contact listed | Recruiting | Not applicable | 600target | 68 / 12 | 2023 | Jul 6, 2026 | |
| NCT06847321 | Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P.… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed | Recruiting | Phase 2 | 300target | 38 / 1 | 2025 | Sep 15, 2026 |